Brothers Martin and Petr Kasa gave the first investor presentation at the October START Day. You will find the answers to questions that came up during the presentation below.
What is your development strategy? Will you expand the product portfolio, consolidate your position in existing markets, or rather expand abroad?
Pilulka has tried to describe the main development strategy in its presentation for investors. We will mainly consolidate our position in existing markets, expand into Hungary, and develop healthcare technologies.
How indebted are you currently, and what is your three-year debt plan?
At the end of 2019, Pilulka recorded liabilities to credit institutions amounting to CZK 76 million. We expect an increase in the credit lines by banks for short-term operating financing in the period 2021-2024.
What is the expected dividend yield? When do you expect the first dividends to be paid?
The future profit will mainly be reinvested in the further growth of Pilulka, and the payment of dividends is not expected yet. Of course, this strategy may change in the future. Due to the extremely rapid sales growth Pilulka is not a dividend title at this stage.
What is your three-year plan for sales, profit margin, profit, and a number of customers by region? What is your three-year expansion plan for foreign markets?
Pilulka expects an average growth of sales at the group level by about 25% per year in the period from 2020 to 2023.
The group-wide gross margin is expected to grow from 26.4% in 2020 to 27.7% in 2023 as a result of the stabilization of activities, the consolidation and a further increase of a market share in new markets. The company expects to achieve a positive group value of the EBITDA indicator of appx. CZK 18 million in 2021, while the EBITDA margin should gradually increase to 2.8% in 2023 and 3.4% in 2024.
The average growth in the number of unique online customers is estimated at 24% (at the group level) between 2020 and 2023.
The business plan for the following years includes the continued development of the business activities of the Czech and Slovak subsidiaries, the consolidation of the market subsidiaries of the Romanian branch, and the opening of a Hungarian subsidiary in 2021.
All information can be found in the documents at www.pilulka.cz/pro-investory
Are you a e-pharmacy, or a e-drugstore?
Online, Pilulka is primarily a platform that connects manufacturers, distributors, and end consumers. In terms of product range, the company focuses on health and body care. In comparison with traditional pharmacies, it has a wider range of products.